Alkermes plc. Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax
Alkermes plc. (ALKS) reported Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax of $15.30 million for the 9-month period ending 2014-09-30, per its 10-Q filed 2015-10-29.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax · last filed 2015-10-29
- Alkermes plc. other comprehensive income (loss), reclassification adjustment from aoci for sale of securities, net of tax for the quarter ending 2014-09-30 was $0.00.
- Alkermes plc. other comprehensive income (loss), reclassification adjustment from aoci for sale of securities, net of tax for the quarter ending 2014-06-30 was $15.30M.
| Period end | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax 3 month | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax 6 month | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax 9 month |
|---|---|---|---|
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-29 | $15.30M derived: sum of 2 quarters · filed 2015-10-29 | $15.30M 10-Q · filed 2015-10-29 |
| 2014-06-30 | $15.30M 10-Q · filed 2015-07-30 | $15.30M 10-Q · filed 2015-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |